+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ex vivo expansion, maturation, and activation of umbilical cord blood-derived T lymphocytes with IL-2, IL-12, anti-CD3, and IL-7: Potential for adoptive cellular immunotherapy post-umbilical cord blood transplantation



Ex vivo expansion, maturation, and activation of umbilical cord blood-derived T lymphocytes with IL-2, IL-12, anti-CD3, and IL-7: Potential for adoptive cellular immunotherapy post-umbilical cord blood transplantation



Experimental Hematology (Charlottesville) 30(3): 245-251



We investigated whether umbilical cord blood (UCB) T cells could be ex vivo expanded and activated in short-term culture for potential utilization as adoptive cellular immunotherapy post-umbilical cord blood transplantation (UCBT). Fresh UCB mononuclear cells (MNCs) were isolated by Ficoll density centrifugation. Cryopreserved UCB mononuclear cells were thawed and washed with 2.5% human serum albumin and 5% dextrose in isotonic saline. The nonadherent MNC fraction were then plated in a serum-free cocktail of IL-2, IL-12, and anti-CD3 with and without IL-7 for 48 hours. Proliferation, cytotoxicity, TH1 (IFN-gamma), CD25, and CD45RO assays were performed. Proliferation studies demonstrated a significant increase in the proliferative ability of the UCB MNCs incubated in anti-CD3, IL-2, IL-12, and IL-7 (fresh--p < 0.005, and thawed--p < 0.001). The combination of all four agonists significantly induced expression of CD45 RO (fresh--p < 0.05, and thawed--p < 0.001) in both the CD4(+) and CD8(+) T cells expressing CD25 (fresh UCB--p < 0.01 [CD4] and p < 0.005 [CD8], respectively; thawed UCB--p < 0.001 [CD4] and p < 0.001 [CD8]). Intracellular cytokine profiles also revealed a significant increase in the production of IFN-gamma (TH1 cells) (fresh UCB--p < 0.005, and thawed UCB--p < 0.001). The combination also significantly increased the killing of K562-labeled target cells (fresh--p < 0.0001, and thawed--0.731 +/- 0.03 vs 0.16 +/- 0.01) (p < 0.001). These data suggest that the ex vivo combination of IL-2, IL-12, anti-CD3, and IL-7 significantly enhances the proliferation, activation, maturation, and cytotoxic potential of UCB T cells of both fresh and thawed UCB MNC. Further studies, however, are required to determine whether these ex vivo--expanded MNC could also potentially exacerbate acute or chronic graft-vs-host disease and/or other toxicities if utilized post-UCBT.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010627951

Download citation: RISBibTeXText

PMID: 11882362

DOI: 10.1016/s0301-472x(01)00781-0


Related references

A novel method for ex-vivo expansion of NK CD3-/CD16+/56+bright/dim subsets expressing increased inhibitory receptors from cryopreserved/thawed/expanded/recryopreserved umbilical cord blood using anti-CD3, IL-2, IL-7 and IL-12 Implications for adoptive cellular immunotherapy post umbilical cord blood transplantation. Blood 102(11): 963a-964a, 2003

Comparison of CTLA-4 expression in umbilical cord blood and adult T-cells and UCB T-cell ex vivo expansion, activation and cytotoxicity with IL-2, IL-7, IL-12, and anti-CD3 Potential cocktail for post UCB transplantation adoptive cellular immunotherapy. Blood 94(10 Suppl. 1 Part 1): 571a, 1999

Anti-CD3/IL-2/IL-7/IL-12 Ex-Vivo Expansion of Previously Cryopreserved and Subsequent Recryopreservation of Umbilical Cord Blood Cytotoxic T Lymphocytes A New Procedure for Adoptive Cellular Immunotherapy Post UCB Transplant. Blood 100(11): Abstract No 208, 2002

Ex vivo expansion of umbilical cord blood derived immature and mature T cells for adoptive immunotherapy. Experimental Hematology (New York) 31(7 Suppl. 1): 207, 2003

Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation. Cancer Research 70(13): 5249-5258, 2010

Ex vivo expansion of human umbilical cord blood-derived T-lymphocytes with homologous cord blood plasma. Tohoku Journal of Experimental Medicine 205(2): 115-122, 2005

Ex vivo expansion of umbilical cord blood with XLCM leads to the preferential expansion, activation and maturation of CD4+ and CD8+ T lymphocytes Development of UCB specific CTLs. Blood 92(10 Suppl. 1 Part 1-2): 543A, 1998

Significant ex vivo expansion of dendritic cells from cord blood mononuclear cells with FLT-3, GM-CSF, IL-4 and TNF alpha Implications for immunotherapy post umbilical cord blood transplant. Blood 90(10 Suppl. 1 Part 2): 348B, 1997

Thawed Umbilical Cord Blood followed by ex vivo engineering with anti-CD3, IL-2, IL-7 and IL-12 followed by recryopreservation significantly expands and activates UCB cytotoxic lymphocytes Potential for UCB Donor lymphocyte infusion post UCB transplantation. Experimental Hematology (Charlottesville) 30(6 Suppl. 1): 137, 2002

Ex vivo expansion of umbilical cord blood with IL-2, IL-7, IL-12 and antiCD3 Activation of UCB cytotoxic T-lymphocytes and potential postnatal therapy for congenital infections. Pediatric Research 47(4 Part 2): 335A, 2000

Expansion of cord blood CD34+ cells in coculture with umbilical vein endothelial cells derived from the same donor is superior to liquid culture Potential use in cord blood transplantation. Blood 96(11 Part 1): 777a, 2000

Ex vivo expansion of cord blood CD34+ cells with autologous umbilical vein endothelial cells from the same donor Potential use in cord blood transplantation. Onkologie 23(Sonderheft 7): 40, 2000

Preclinical characterization of DUOC-01, a cell therapy product derived from banked umbilical cord blood for use as an adjuvant to umbilical cord blood transplantation for treatment of inherited metabolic diseases. CytoTherapy 17(6): 803-815, 2015

Reprint of: Preclinical characterization of DUOC-01, a cell therapy product derived from banked umbilical cord blood for use as an adjuvant to umbilical cord blood transplantation for treatment of inherited metabolic diseases. CytoTherapy 17(9): 1314-1326, 2015

Umbilical cord blood-derived mesenchymal cell fate after mouse umbilical cord blood transplantation. Transplantation 90(9): 1037-1039, 2010